TY - JOUR
T1 - The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry
T2 - A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization
AU - Nasrallah, Henry A.
AU - Harvey, Philip D.
AU - Casey, Daniel
AU - Csoboth, Csilla T.
AU - Hudson, James I.
AU - Julian, Laura
AU - Lentz, Ellen
AU - Nuechterlein, Keith H.
AU - Perkins, Diana O.
AU - Kotowsky, Nirali
AU - Skale, Tracey G.
AU - Snowden, Lonnie R.
AU - Tandon, Rajiv
AU - Tek, Cenk
AU - Velligan, Dawn
AU - Vinogradov, Sophia
AU - O'Gorman, Cedric
N1 - Funding Information:
Henry Nasrallah has received research grants from Forest, Forum, Genentech and Otsuka and has been a consultant and on the speaker's bureau for Boehringer-Ingelheim, Genentech, Forum, Janssen, Lundbeck, Merck, Novartis, Otsuka, Sunovion and Teva. Philip Harvey has received consulting fees from Abbvie, Boehringer-Ingelheim, Forum Pharma, Forest labs, Genentech, Otsuka-America, Roche Pharma, Sunovion Pharma and Takeda Pharma. Daniel Casey is a consultant to Genentech. James Hudson has received consulting fees from Genentech, Roche and Shire and has received research grant support from Genentech and Shire. Keith Nuechterlein is a paid consultant to Genentech and also serves as a consultant to Janssen Scientific Affairs, Otsuka and PositScience. Diana Perkins is a consultant and research grant recipient for Genentech/Roche and a consultant for Otsuka/Lundbeck, Sunovion and Janssen Pharmaceuticals. Tracey Skale is a consultant for Merck, Sunivion and Otsuka/Lundbeck. Lonnie Snowden has no conflicts of interest related to this manuscript. Rajiv Tandon was an investigator on the MOSAIC Schizophrenia registry and has no other conflicts of interest related to this manuscript. Cenk Tek is a consultant and has received grant support from Roche. Dawn Velligan is a consultant and is on the advisory board for Genentech/Roche, a consultant, and on the advisory board and speaker's bureau for Otsuka/Lundbeck, a consultant and research grant recipient for Amgen Pharmaceuticals, a consultant and on the speaker's bureau for Janssen Pharmaceuticals, a consultant for Takeda Pharmaceuticals and a consultant for AbbVie Pharmaceuticals. Sophia Vinogradov is a paid consultant of PositScience, Inc. and Forum Pharmaceuticals. Nirali Kotowsky is an employee of Genentech/Roche. Csilla Csoboth , Laura Julian and Ellen Lentz are employees and stockholders of Genentech/Roche. Cedric O'Gorman was an employee and stockholder of Genentech/Roche at the time the study was performed.
Funding Information:
The authors received medical editing support from inVentiv Medical Communications, which was funded by F. Hoffmann-La Roche Ltd. The authors would also like to thank all the investigators, their site staff, and research participants and their caregivers in collection of these data.
Publisher Copyright:
© 2015 Elsevier B.V.
PY - 2015/1/5
Y1 - 2015/1/5
N2 - Background: The Management of Schizophrenia in Clinical Practice (MOSAIC), a disease-based registry of schizophrenia, was initiated in December 2012 to address important gaps in our understanding of the impact and burden of schizophrenia and to provide insight into the current status of schizophrenia care in the US. Recruitment began in December 2012 with ongoing assessment continuing through May 2014. Methods: Participants were recruited from a network of 15 centralized Patient Assessment Centers supporting proximal care sites. Broad entry criteria included patients diagnosed with schizophrenia, schizophreniform or schizoaffective disorder, presenting within the normal course of care, in usual treatment settings, aged ≥. 18. years and able to read and speak English. Results: By May 2014, 550 participants (65.8% male, 59.8% White, 64.4% single, mean age 42.9. years), were enrolled. The majority had a diagnosis of schizophrenia (62.0%). Mean illness duration at entry was 15.0. years. Common comorbidities at entry were high lipid levels (26.9%), hypertension (23.1%) and type II diabetes (13%). Participants were categorized by baseline overall Clinical Global Impression-Schizophrenia Severity Score as minimally (9.1%), mildly (25.3%), moderately (39.9%), markedly (22.3%) and severely (3.4%) ill. Most commonly used second generation antipsychotics at entry were risperidone (17.8%), clozapine (16.5%), olanzapine (14.0%), aripiprazole (13.6%) and quetiapine (5.6%). Conclusions: No large-scale patient registry has been conducted in the US to longitudinally follow patients with schizophrenia and describe symptom attributes, support network, care access and disease burden. These data provide important epidemiological, clinical and outcome insights into the burden of schizophrenia in the US.
AB - Background: The Management of Schizophrenia in Clinical Practice (MOSAIC), a disease-based registry of schizophrenia, was initiated in December 2012 to address important gaps in our understanding of the impact and burden of schizophrenia and to provide insight into the current status of schizophrenia care in the US. Recruitment began in December 2012 with ongoing assessment continuing through May 2014. Methods: Participants were recruited from a network of 15 centralized Patient Assessment Centers supporting proximal care sites. Broad entry criteria included patients diagnosed with schizophrenia, schizophreniform or schizoaffective disorder, presenting within the normal course of care, in usual treatment settings, aged ≥. 18. years and able to read and speak English. Results: By May 2014, 550 participants (65.8% male, 59.8% White, 64.4% single, mean age 42.9. years), were enrolled. The majority had a diagnosis of schizophrenia (62.0%). Mean illness duration at entry was 15.0. years. Common comorbidities at entry were high lipid levels (26.9%), hypertension (23.1%) and type II diabetes (13%). Participants were categorized by baseline overall Clinical Global Impression-Schizophrenia Severity Score as minimally (9.1%), mildly (25.3%), moderately (39.9%), markedly (22.3%) and severely (3.4%) ill. Most commonly used second generation antipsychotics at entry were risperidone (17.8%), clozapine (16.5%), olanzapine (14.0%), aripiprazole (13.6%) and quetiapine (5.6%). Conclusions: No large-scale patient registry has been conducted in the US to longitudinally follow patients with schizophrenia and describe symptom attributes, support network, care access and disease burden. These data provide important epidemiological, clinical and outcome insights into the burden of schizophrenia in the US.
KW - Disease burden
KW - Disease characteristics
KW - Functioning
KW - Registry
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84955349044&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955349044&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2015.04.031
DO - 10.1016/j.schres.2015.04.031
M3 - Article
C2 - 26027848
AN - SCOPUS:84955349044
VL - 166
SP - 69
EP - 79
JO - Schizophrenia Research
JF - Schizophrenia Research
SN - 0920-9964
IS - 1-3
ER -